Pharmacokinetic and pharmacodynamic analysis of combined chemotherapy with carboplatin and paclitaxel for patients with ovarian cancer

2001 ◽  
Vol 6 (5) ◽  
pp. 248-252 ◽  
Author(s):  
A. Arakawa ◽  
H. Nishikawa ◽  
K. Suzumori ◽  
N. Kato
Keyword(s):  
Ovarian Cancer ◽  
Combined Chemotherapy ◽  
Pharmacodynamic Analysis

scholarly journals Combined chemotherapy and allogeneic human Vγ9Vδ2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo

2019 ◽  
Vol 8 (11) ◽  
pp. e1649971 ◽  
Author(s):  
Noémie Joalland ◽  
Laura Lafrance ◽  
Thibauld Oullier ◽  
Séverine Marionneau-Lambot ◽  
Delphine Loussouarn ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Cells ◽  
T Lymphocyte ◽  
Ovarian Cancer Cells ◽  
Combined Chemotherapy

scholarly journals The Serum Level of Vascular Endothelial Growth Factor (VEGF) is Declined after Paclitaxel-Carboplatin Combined Chemotherapy Treatment on Epithelial Ovarian Cancer

2016 ◽  
Author(s):  
Amelia Abdullah
Keyword(s):  
Ovarian Cancer ◽  
Cell Differentiation ◽  
Serum Level ◽  
Epithelial Ovarian Cancer ◽  
Early Stage ◽  
Clinical Staging ◽  
Teaching Hospitals ◽  
Advanced Stage ◽  
Combined Chemotherapy ◽  
Differentiated Cells

Objective: To assess the effect of Paclitaxel-Carboplatin combination on epithelial ovarian cancer by studying the changes in VEGF serum levels after receiving 3 series of chemotherapy. Methods: This was a cohort study conducted at several teaching hospitals in Obstetrics and Gynecology Department of the Faculty of Medicine, Hasanuddin University from April 2011 to March 2012. The subjects were patients with ovarian cancer who met the inclusion criteria and had undergone surgery. The clinical staging was determined with 2009 FIGO criteria. They went through histopathology examination to determine the histological type and cell differentiation of the lesion. They also went through combined chemotherapy of Paclitaxel and Carboplatin. The data were analyzed with paired t-test. Results: The study reveals that out of 30 cases of ovarian cancer who received a combination chemotherapy, most were < 45 years of age (53.33%), nulliparous (46.7%), serosum type (53.3%), with moderate differentiation (36.7%), and in advanced stage (73.3%). The VEGF serum level after 3 series of chemotherapy was lower than before (the average value: 294.67 vs 572.77 ng/ml). There was a significant change in VEGF serum level after receiving chemotherapy (p=0.000). The VEGF serum level of advanced-stage and early stage epithelial ovarian cancer after chemotherapy decreases significantly (p=0.000 and p=0.011). The advanced-stage cases showed more responses to chemotherapy than the early-stage did. There was a tendency that adenocarcinoma serosum type was more responsive to the therapy than mucinosum type (p=0.000 vs 0.003). Conclusion: There is no difference in VEGF serum level based on cell differentiation but there is a tendency that well and moderate differentiated cells have a greater change than the poor differentiated cells (p=0.003, p=0.003 vs p=0.019). [Indones J Obstet Gynecol 2012; 36-3: 135-9] Keywords: carboplatin, epithelial ovarian cancer, paclitaxel, VEGF

Factors of the ovarian cancer resistance to combined chemotherapy with platinum preparations

1996 ◽  
Vol 122 (6) ◽  
pp. 1213-1216 ◽  
Author(s):  
A. G. Blyumenberg ◽  
L. B. Gorbacheva ◽  
V. A. Gorbunova ◽  
V. P. Kozachenko ◽  
V. Z. Lankin
Keyword(s):  
Ovarian Cancer ◽  
Combined Chemotherapy ◽  
Cancer Resistance ◽  
Platinum Preparations

Impact of extended cycles of chemotherapy on survival outcome in recurrent epithelial ovarian cancer

2020 ◽  
Vol 159 ◽  
pp. 346-347
Author(s):  
W.Y. Hwang ◽  
S.I. Kim ◽  
M. Lee ◽  
K. Kim ◽  
J.H. No ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Survival Outcome
Sign in / Sign up

Export Citation Format

Share Document